Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896932 | 0.81 | ATM (0.36) | MMP2ANPEPATM | |
| SCHEMBL9736868 | 0.80 | ALDH1A1 (0.39) | MMP2ANPEPCA12 | |
| SCHEMBL1251161 | 0.80 | ATM (0.42) | MMP2ANPEPATM | |
| SCHEMBL21682443 | 0.80 | ATM (0.42) | MMP2ANPEPATM | |
| SCHEMBL1251167 | 0.80 | ATM (0.42) | MMP2ANPEPATM | |
| SCHEMBL1251163 | 0.80 | ATM (0.42) | MMP2ANPEPATM | |
| SCHEMBL6917231 | 0.80 | ATM (0.42) | MMP2ANPEPATM | |
| SCHEMBL5397387 | 0.80 | CA12 (0.47) | MMP2ANPEPCA12MMP9 | |
| SCHEMBL5397377 | 0.80 | CA12 (0.47) | MMP2ANPEPCA12MMP9 | |
| SCHEMBL5397381 | 0.80 | CA12 (0.47) | MMP2ANPEPCA12MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199569-A1 | Pyrrolidine derivatives | AEBI JOHANNES (CH) | 2003-10-23 | — | — | US | disclosed |
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020040048-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| US-5475117-A | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5371235-A | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER INC. (US) | 1994-12-06 | — | — | US | disclosed |
| US-5157125-A | Optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5095121-A | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1)heptanes | PFIZER INC (US) | 1992-03-10 | — | — | US | disclosed |
| US-5013839-A | Process for optically active 2-alkyl-2,5-diazabicyclo(2.2.1) heptanes | PFIZER INC. (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199569-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | MMP2 58/4885ANPEP 51/4885ATM 4665/4885 |
| US-20020040048-A1 | PYRROLIDINE COMPOUNDS | PREP, PEPD, MMP3 | MMP2 45/4885ANPEP 59/4885ATM 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.